Signet Financial Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
ACA
MCMC
CI
Signet Financial Management's XBI Position: Q1 2022 in Review
Signet Financial Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 425 shares — an estimated $48K sold.
Signet Financial Management first reported a position in XBI in Q4 2021 and held it in 1 quarter. The position peaked at $48K in Q4 2021. 703 funds tracked by Wall St. Rank hold XBI as of Q1 2022.
- Signet Financial Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
- Signet Financial Management sold 425 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $48K.
- Signet Financial Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and held it in 1 quarter.
- Signet Financial Management's State Street SPDR S&P Biotech ETF position peaked at $48K in Q4 2021.
- 703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.
Based on Signet Financial Management's 13F filing for Q1 2022, filed 13 May 2022.